AB Corporate Bond ETF (NASDAQ:EYEG) Short Interest Update

AB Corporate Bond ETF (NASDAQ:EYEG) was the recipient of a large growth in short interest during the month of August. As of August 31st, there was short interest totaling 1,040 shares, a growth of 1,233.3% from the August 15th total of 78 shares. Based on an average daily volume of 668 shares, the days-to-cover ratio is currently 1.6 days. Currently, 0.0% of the shares of the stock are short sold.

AB Corporate Bond ETF Trading Down 0.4%

NASDAQ:EYEG traded down $0.15 on Thursday, reaching $34.11. The stock had a trading volume of 14 shares, compared to its average volume of 300. AB Corporate Bond ETF has a 12-month low of $34.01 and a 12-month high of $36.63. The company has a market cap of $27.29 million, a price-to-earnings ratio of -20.30 and a beta of 0.18. The firm’s fifty day moving average is $34.64 and its two-hundred day moving average is $35.09. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.07 and a quick ratio of 3.07.

AB Corporate Bond ETF Cuts Dividend

The company also recently disclosed a monthly dividend, which was paid on Friday, September 4th. Investors of record on Tuesday, September 1st were paid a dividend of $0.1284 per share. The ex-dividend date of this dividend was Tuesday, September 1st. This represents a c) annualized dividend and a dividend yield of 4.5%. AB Corporate Bond ETF’s dividend payout ratio is presently -101.79%.

Institutional Trading of AB Corporate Bond ETF

An institutional investor recently bought a new position in AB Corporate Bond ETF stock. Kestra Advisory Services LLC bought a new position in AB Corporate Bond ETF (NASDAQ:EYEG) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 951 shares of the specialty pharmaceutical company’s stock, valued at approximately $34,000. Kestra Advisory Services LLC owned 0.13% of AB Corporate Bond ETF as of its most recent filing with the Securities and Exchange Commission. 64.16% of the stock is owned by hedge funds and other institutional investors.

About AB Corporate Bond ETF

EyeGate Pharmaceuticals, Inc is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.